Mortality predictors in hospitalised COVID-19 patients and the role of anti-SARS-CoV-2 IgG antibodies and remdesivir
In a pre-vaccination era serologic tests may be used to evaluate the seroprevalence and efficacy of containment strategies applied to the community. Subsequently, SARS-CoV-2 vaccination has successfully reduced hospitalization and admission to intensive care. The role of antiviral treatment for COVI...
Gespeichert in:
| Veröffentlicht in: | Le infezioni in medicina 2023, Vol.31 (2), p.215-224 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 224 |
|---|---|
| container_issue | 2 |
| container_start_page | 215 |
| container_title | Le infezioni in medicina |
| container_volume | 31 |
| creator | Venturini, Sergio Orso, Daniele Cugini, Francesco Villalta, Danilo Tonizzo, Maurizio Grembiale, Alessandro Zanier, Ada Cecco, Serena Callegari, Astrid Duranti, Silvia Del Fabro, Giovanni Crapis, Massimo |
| description | In a pre-vaccination era serologic tests may be used to evaluate the seroprevalence and efficacy of containment strategies applied to the community. Subsequently, SARS-CoV-2 vaccination has successfully reduced hospitalization and admission to intensive care. The role of antiviral treatment for COVID-19 remains debated.
We investigated the effect of SARS-CoV-2 IgG Spike (S) antibody responses in hospitalized patients on 30-day mortality. Finally, we assessed whether other predictive factors affected mortality after 30 days.
Observational study on COVID-19 patients admitted from October 1, 2021, to January 30, 2022.
520 patients were studied; 108 died at the 30-day follow-up (21%). A borderline significance for mortality was observed in favour of the high antibody titer group (24% vs 17%, p=0.05). From the univariate Cox regression analysis, a high IgG-S titer was significantly correlated to lower 30-day mortality (p=0.04, HR: 0.7; 95%CI: 0.44-0.98). The administration of remdesivir (p=0.01) and the age |
| doi_str_mv | 10.53854/liim-3102-10 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10241404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37283645</sourcerecordid><originalsourceid>FETCH-LOGICAL-p182t-9f496d4676acf7cfe82c74c8e3298dc09c3cfe3014f20cbca3c3f7b38082d4bd3</originalsourceid><addsrcrecordid>eNpVkF9LwzAUxYMobsw9-ir5AtH8a5s8yag6B5OB072WNEm3SNuUNA727a1ORe_L5Z5z74_LAeCS4OuEiYTf1M41iBFMEcEnYEwTRpFIhTwFY0IoR5JJPALTvn_DQ6WYSCnOwYhlVLCUJ2MQn3yIqnbxALtgjdPRhx66Fu5837lPp7cG5qvN4g4RCTsVnW1jD1VrYNxZGHxtoa-GOTq0nj2vUe43iMLFdv6lld44e1wPtjG2d3sXLsBZpereTr_7BLw-3L_kj2i5mi_y2RJ1RNCIZMVlaniapUpXma6soDrjWlhGpTAaS80GkWHCK4p1qRXTrMpKJrCghpeGTcDtkdu9l401evg8qLrogmtUOBReueK_07pdsfX7YgiUE475QLj6S_g9_QmQfQDegXVt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mortality predictors in hospitalised COVID-19 patients and the role of anti-SARS-CoV-2 IgG antibodies and remdesivir</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Venturini, Sergio ; Orso, Daniele ; Cugini, Francesco ; Villalta, Danilo ; Tonizzo, Maurizio ; Grembiale, Alessandro ; Zanier, Ada ; Cecco, Serena ; Callegari, Astrid ; Duranti, Silvia ; Del Fabro, Giovanni ; Crapis, Massimo</creator><creatorcontrib>Venturini, Sergio ; Orso, Daniele ; Cugini, Francesco ; Villalta, Danilo ; Tonizzo, Maurizio ; Grembiale, Alessandro ; Zanier, Ada ; Cecco, Serena ; Callegari, Astrid ; Duranti, Silvia ; Del Fabro, Giovanni ; Crapis, Massimo</creatorcontrib><description>In a pre-vaccination era serologic tests may be used to evaluate the seroprevalence and efficacy of containment strategies applied to the community. Subsequently, SARS-CoV-2 vaccination has successfully reduced hospitalization and admission to intensive care. The role of antiviral treatment for COVID-19 remains debated.
We investigated the effect of SARS-CoV-2 IgG Spike (S) antibody responses in hospitalized patients on 30-day mortality. Finally, we assessed whether other predictive factors affected mortality after 30 days.
Observational study on COVID-19 patients admitted from October 1, 2021, to January 30, 2022.
520 patients were studied; 108 died at the 30-day follow-up (21%). A borderline significance for mortality was observed in favour of the high antibody titer group (24% vs 17%, p=0.05). From the univariate Cox regression analysis, a high IgG-S titer was significantly correlated to lower 30-day mortality (p=0.04, HR: 0.7; 95%CI: 0.44-0.98). The administration of remdesivir (p=0.01) and the age <65 years (p=2.3e-05) were found to be protective for the considered outcome (respectively, HR: 0.5, 95%CI: 0.34-0.86, and HR: 0.1, 95%CI: 0.04-0.30).
S-antibodies and remdesivir could play a protecting role in increasing the survival of hospitalized COVID-19 patients who are not suffering from a critical disease. Advanced age is a risk factor for poor outcomes among infected people.</description><identifier>ISSN: 1124-9390</identifier><identifier>EISSN: 2532-8689</identifier><identifier>DOI: 10.53854/liim-3102-10</identifier><identifier>PMID: 37283645</identifier><language>eng</language><publisher>Italy: InfezMed</publisher><subject>Original</subject><ispartof>Le infezioni in medicina, 2023, Vol.31 (2), p.215-224</ispartof><rights>2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241404/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241404/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,4012,27906,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37283645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Venturini, Sergio</creatorcontrib><creatorcontrib>Orso, Daniele</creatorcontrib><creatorcontrib>Cugini, Francesco</creatorcontrib><creatorcontrib>Villalta, Danilo</creatorcontrib><creatorcontrib>Tonizzo, Maurizio</creatorcontrib><creatorcontrib>Grembiale, Alessandro</creatorcontrib><creatorcontrib>Zanier, Ada</creatorcontrib><creatorcontrib>Cecco, Serena</creatorcontrib><creatorcontrib>Callegari, Astrid</creatorcontrib><creatorcontrib>Duranti, Silvia</creatorcontrib><creatorcontrib>Del Fabro, Giovanni</creatorcontrib><creatorcontrib>Crapis, Massimo</creatorcontrib><title>Mortality predictors in hospitalised COVID-19 patients and the role of anti-SARS-CoV-2 IgG antibodies and remdesivir</title><title>Le infezioni in medicina</title><addtitle>Infez Med</addtitle><description>In a pre-vaccination era serologic tests may be used to evaluate the seroprevalence and efficacy of containment strategies applied to the community. Subsequently, SARS-CoV-2 vaccination has successfully reduced hospitalization and admission to intensive care. The role of antiviral treatment for COVID-19 remains debated.
We investigated the effect of SARS-CoV-2 IgG Spike (S) antibody responses in hospitalized patients on 30-day mortality. Finally, we assessed whether other predictive factors affected mortality after 30 days.
Observational study on COVID-19 patients admitted from October 1, 2021, to January 30, 2022.
520 patients were studied; 108 died at the 30-day follow-up (21%). A borderline significance for mortality was observed in favour of the high antibody titer group (24% vs 17%, p=0.05). From the univariate Cox regression analysis, a high IgG-S titer was significantly correlated to lower 30-day mortality (p=0.04, HR: 0.7; 95%CI: 0.44-0.98). The administration of remdesivir (p=0.01) and the age <65 years (p=2.3e-05) were found to be protective for the considered outcome (respectively, HR: 0.5, 95%CI: 0.34-0.86, and HR: 0.1, 95%CI: 0.04-0.30).
S-antibodies and remdesivir could play a protecting role in increasing the survival of hospitalized COVID-19 patients who are not suffering from a critical disease. Advanced age is a risk factor for poor outcomes among infected people.</description><subject>Original</subject><issn>1124-9390</issn><issn>2532-8689</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkF9LwzAUxYMobsw9-ir5AtH8a5s8yag6B5OB072WNEm3SNuUNA727a1ORe_L5Z5z74_LAeCS4OuEiYTf1M41iBFMEcEnYEwTRpFIhTwFY0IoR5JJPALTvn_DQ6WYSCnOwYhlVLCUJ2MQn3yIqnbxALtgjdPRhx66Fu5837lPp7cG5qvN4g4RCTsVnW1jD1VrYNxZGHxtoa-GOTq0nj2vUe43iMLFdv6lld44e1wPtjG2d3sXLsBZpereTr_7BLw-3L_kj2i5mi_y2RJ1RNCIZMVlaniapUpXma6soDrjWlhGpTAaS80GkWHCK4p1qRXTrMpKJrCghpeGTcDtkdu9l401evg8qLrogmtUOBReueK_07pdsfX7YgiUE475QLj6S_g9_QmQfQDegXVt</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Venturini, Sergio</creator><creator>Orso, Daniele</creator><creator>Cugini, Francesco</creator><creator>Villalta, Danilo</creator><creator>Tonizzo, Maurizio</creator><creator>Grembiale, Alessandro</creator><creator>Zanier, Ada</creator><creator>Cecco, Serena</creator><creator>Callegari, Astrid</creator><creator>Duranti, Silvia</creator><creator>Del Fabro, Giovanni</creator><creator>Crapis, Massimo</creator><general>InfezMed</general><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>2023</creationdate><title>Mortality predictors in hospitalised COVID-19 patients and the role of anti-SARS-CoV-2 IgG antibodies and remdesivir</title><author>Venturini, Sergio ; Orso, Daniele ; Cugini, Francesco ; Villalta, Danilo ; Tonizzo, Maurizio ; Grembiale, Alessandro ; Zanier, Ada ; Cecco, Serena ; Callegari, Astrid ; Duranti, Silvia ; Del Fabro, Giovanni ; Crapis, Massimo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p182t-9f496d4676acf7cfe82c74c8e3298dc09c3cfe3014f20cbca3c3f7b38082d4bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venturini, Sergio</creatorcontrib><creatorcontrib>Orso, Daniele</creatorcontrib><creatorcontrib>Cugini, Francesco</creatorcontrib><creatorcontrib>Villalta, Danilo</creatorcontrib><creatorcontrib>Tonizzo, Maurizio</creatorcontrib><creatorcontrib>Grembiale, Alessandro</creatorcontrib><creatorcontrib>Zanier, Ada</creatorcontrib><creatorcontrib>Cecco, Serena</creatorcontrib><creatorcontrib>Callegari, Astrid</creatorcontrib><creatorcontrib>Duranti, Silvia</creatorcontrib><creatorcontrib>Del Fabro, Giovanni</creatorcontrib><creatorcontrib>Crapis, Massimo</creatorcontrib><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Le infezioni in medicina</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venturini, Sergio</au><au>Orso, Daniele</au><au>Cugini, Francesco</au><au>Villalta, Danilo</au><au>Tonizzo, Maurizio</au><au>Grembiale, Alessandro</au><au>Zanier, Ada</au><au>Cecco, Serena</au><au>Callegari, Astrid</au><au>Duranti, Silvia</au><au>Del Fabro, Giovanni</au><au>Crapis, Massimo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mortality predictors in hospitalised COVID-19 patients and the role of anti-SARS-CoV-2 IgG antibodies and remdesivir</atitle><jtitle>Le infezioni in medicina</jtitle><addtitle>Infez Med</addtitle><date>2023</date><risdate>2023</risdate><volume>31</volume><issue>2</issue><spage>215</spage><epage>224</epage><pages>215-224</pages><issn>1124-9390</issn><eissn>2532-8689</eissn><abstract>In a pre-vaccination era serologic tests may be used to evaluate the seroprevalence and efficacy of containment strategies applied to the community. Subsequently, SARS-CoV-2 vaccination has successfully reduced hospitalization and admission to intensive care. The role of antiviral treatment for COVID-19 remains debated.
We investigated the effect of SARS-CoV-2 IgG Spike (S) antibody responses in hospitalized patients on 30-day mortality. Finally, we assessed whether other predictive factors affected mortality after 30 days.
Observational study on COVID-19 patients admitted from October 1, 2021, to January 30, 2022.
520 patients were studied; 108 died at the 30-day follow-up (21%). A borderline significance for mortality was observed in favour of the high antibody titer group (24% vs 17%, p=0.05). From the univariate Cox regression analysis, a high IgG-S titer was significantly correlated to lower 30-day mortality (p=0.04, HR: 0.7; 95%CI: 0.44-0.98). The administration of remdesivir (p=0.01) and the age <65 years (p=2.3e-05) were found to be protective for the considered outcome (respectively, HR: 0.5, 95%CI: 0.34-0.86, and HR: 0.1, 95%CI: 0.04-0.30).
S-antibodies and remdesivir could play a protecting role in increasing the survival of hospitalized COVID-19 patients who are not suffering from a critical disease. Advanced age is a risk factor for poor outcomes among infected people.</abstract><cop>Italy</cop><pub>InfezMed</pub><pmid>37283645</pmid><doi>10.53854/liim-3102-10</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1124-9390 |
| ispartof | Le infezioni in medicina, 2023, Vol.31 (2), p.215-224 |
| issn | 1124-9390 2532-8689 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10241404 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Original |
| title | Mortality predictors in hospitalised COVID-19 patients and the role of anti-SARS-CoV-2 IgG antibodies and remdesivir |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A36%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mortality%20predictors%20in%20hospitalised%20COVID-19%20patients%20and%20the%20role%20of%20anti-SARS-CoV-2%20IgG%20antibodies%20and%20remdesivir&rft.jtitle=Le%20infezioni%20in%20medicina&rft.au=Venturini,%20Sergio&rft.date=2023&rft.volume=31&rft.issue=2&rft.spage=215&rft.epage=224&rft.pages=215-224&rft.issn=1124-9390&rft.eissn=2532-8689&rft_id=info:doi/10.53854/liim-3102-10&rft_dat=%3Cpubmed%3E37283645%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37283645&rfr_iscdi=true |